New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
07:41 EDTNBSNeoStem presents results for Phase 1 study of autologous Treg immunotherapy
NeoStem announced the presentation of the results of an open-label dose escalation Phase 1 clinical study of autologous T regulatory cell, or Treg, immunotherapy for type 1 diabetes mellitus, or T1DM, indicating safety and tolerability following administration. As reported by UCSF, in the study, 14 patients between 18 and 45 years of age with a mean duration of disease of 10 months all of whom retained a baseline level of insulin production, received a single infusion of autologous Tregs expanded ~500-fold. The infusions were well tolerated; the majority of adverse events reported were mild. Infused Tregs peaked in circulation 3-7 days after infusion and were detectable at greater than 6 months. The average levels of stimulated C-peptide, an indicator of pancreatic islets beta cell function, for some patients remained stable from baseline for as long as 2 years post treatment. These data suggest that the treatment was safe and did not adversely affect residual beta cell function. The Tregs were observed to be highly functional and long lived in treated individuals. While the U.S. Phase 1 study was designed to evaluate safety and tolerability in adults who have suffered T1DM for various durations, supportive evidence of the utility of Tregs for T1DM in humans was provided by a study of pediatric patients with new onset T1DM. After 12 months of follow-up, about 66 percent of children treated were in remission, compared to only 20 percent of concurrent controls, and two Treg treated children achieved complete insulin independence, while none of the control children achieved this endpoint. Initiation of Phase 2 study is expected for Q3.
News For NBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
08:31 EDTNBSNeoStem plans to change name to Caladrius Biosciences
Subscribe for More Information
May 28, 2015
09:27 EDTNBSOn The Fly: Pre-market Movers
HIGHER: Rally Software (RALY), up 44% after deal to be bought by CA Technologies for $19.50 per share... IMAX (IMAX), up 6.5% after IMAX China files application for IPO on Hong Kong Stock Exchange... Avago (AVGO), up 2.8% after announcing deal to buy Broadcom (BRCM) for $37B in cash and stock. Broadcom shares are down 1% following the announcement... Western Digital (WDC), up 2.4% following upgrade to Buy from Neutral at Goldman. UP AFTER EARNINGS: Express (EXPR), up 8%... Abercrombie & Fitch (ANF), up 4.3%. LOWER: NeoStem (NBS), down 22.8% after 12.5M share secondary price at $2 per share... (CTRP), down 1.6% after reportedly disclosing cyberattack against its services. DOWN AFTER EARNINGS: Orbital ATK (OA), down 1.6%... Signet (SIG), down 3.5%... Sanderson Farms (SAFM), down 3%... Dangdang (DANG), down 11%.
May 27, 2015
19:14 EDTNBSOn The Fly: After Hours Movers
Subscribe for More Information
18:55 EDTNBSNeoStem 12.5M share Secondary priced at $2.00
Aegis acted as sole book running manager for the offering.
16:02 EDTNBSNeoStem files to sell common stock, no amount given
Aegis Capital Corp. is acting as sole book-running manager for the offering
May 26, 2015
07:33 EDTNBSNeoStem appoints Merrick Ross as lead for NeoStem's Intus study
Subscribe for More Information
May 21, 2015
15:19 EDTNBSNeoStem spikes higher, levels to watch
The shares are spiking sharply, last up more than 45% to $3.30. At that price next resistance is at the session high at $3.47 and then at $3.71. Support is at $3.17.
15:17 EDTNBSNeoStem up over 40% after getting $17.7M grant for metastatic melanoma treatment
Subscribe for More Information
15:15 EDTNBSNeoStem gets $17.7M grant for metastatic melanoma treatment
Subscribe for More Information
15:11 EDTNBSNeoStem gets $17.7M grant from CIRM

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use